RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development

Y Bai, Y Qiao, M Li, W Yang, H Chen, Y Wu… - European Journal of …, 2024 - Elsevier
Within the field of medical science, there is a great deal of interest in investigating cell death
pathways in the hopes of discovering new drugs. Over the past two decades …

Pharmaceutical Therapies for Necroptosis in Myocardial Ischemia–Reperfusion Injury

Y Zhang, Y Zhang, J Zang, Y Li, X Wu - Journal of Cardiovascular …, 2023 - mdpi.com
Cardiovascular disease morbidity/mortality are increasing due to an aging population and
the rising prevalence of diabetes and obesity. Therefore, innovative cardioprotective …

p55γ degrades RIP3 via MG53 to suppress ischaemia-induced myocardial necroptosis and mediates cardioprotection of preconditioning

Z Li, R Dai, M Chen, L Huang, K Zhu, M Li… - Cardiovascular …, 2023 - academic.oup.com
Aims Regulated necrosis (necroptosis) and apoptosis are important biological features of
myocardial infarction, ischaemia-reperfusion (I/R) injury, and heart failure. However, the …

Multipronged regulation of autophagy and apoptosis: emerging role of TRIM proteins

N Ahsan, M Shariq, A Surolia, R Raj, MF Khan… - Cellular & Molecular …, 2024 - Springer
TRIM proteins are characterized by their conserved N-terminal RING, B-box, and coiled-coil
domains. These proteins are efficient regulators of autophagy, apoptosis, and innate …

Mitsugumin 53 mitigation of ischemia–reperfusion injury in a mouse model

DA Gouchoe, YG Lee, JL Kim, Z Zhang… - The Journal of Thoracic …, 2024 - Elsevier
Objective Primary graft dysfunction is often attributed to ischemia–reperfusion injury, and
prevention would be a therapeutic approach to mitigate injury. Mitsugumin 53, a myokine, is …

Activation of MG53 Enhances Cell Survival and Engraftment of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Injured Hearts

KH Park, X He, L Jiang, H Zhu, J Liang, Y Wang… - Stem Cell Reviews and …, 2023 - Springer
Abstract Background and Objective Our previous studies demonstrated that MG53 protein
can protect the myocardium, but its use as a therapeutic is challenging due to its short half …

Protective role of MG53 against ischemia/reperfusion injury on multiple organs: A narrative review

B Xu, C Wang, H Chen, L Zhang, L Gong… - Frontiers in …, 2022 - frontiersin.org
Ischemia/reperfusion (I/R) injury is a common clinical problem after coronary angioplasty,
cardiopulmonary resuscitation, and organ transplantation, which can lead to cell damage …

MG53: A new protagonist in the precise treatment of cardiomyopathies

Q Zhao, Q Zhang, X Zhao, Z Tian, M Sun… - Biochemical Pharmacology, 2024 - Elsevier
Cardiomyopathies (CMs) are highly heterogeneous progressive heart diseases
characterised by structural and functional abnormalities of the heart, whose intricate …

Knowledge mapping and emerging trends of ferroptosis in ischemia reperfusion injury research: A bibliometric analysis (2013–2022)

N Sun, Y Xing, J Jiang, P Wu, L Qing, J Tang - Heliyon, 2023 - cell.com
Abstract Objective Ischemia/reperfusion (I/R) injury is an inevitable dilemma when
previously ischemic multiple organs and tissues are returned to a state of blood flow, with …

The next Frontier in lung transplantation: protecting the endothelium and repairing organs for transplant utilizing MG53

DA Gouchoe, BA Whitson… - Clinical and Translational …, 2023 - search.proquest.com
Additionally, DAMPs can initiate release of tumor necrosis factor-alpha (TNF-α), which when
bound to its receptors recruits cytosolic adaptor proteins to form complex I (which contains …